Anavex Appoints Leading Alzheimer’s Disease Expert Dr. Mark Smith to Scientific Advisory Board

Anavex Scales Up Synthesis of ANAVEX 2-73 for Phase 1 Alzheimer’s Disease Study

Ground-Breaking Anti-Amnesic and Neuroprotective Effects of Alzheimer’s Compound ANAVEX 1-41 Published in Journal of Neuropsychopharmacology

Anavex Presents Potent Neuroprotective Effects of ANAVEX 1-41 at Neuroscience 2008

Anavex Completes Successful Preclinical Studies on Lead Alzheimer’s Drug Candidate

Anavex Presents Neuroprotective Effects of ANAVEX 1-41 at the International Conference on Alzheimer’s Disease 2008

Anavex Life Sciences Corp. Will Present New Findings at the International Conference on Alzheimer’s Disease 2008 (July 26-31, 2008, Chicago, USA)

Anavex Further Strengthens Board of Directors

Anavex Announces Appointment of Oncology Specialist to Board of Directors